Source link : https://newshealth.biz/health-news/durvalumab-plus-bcg-cut-early-recurrence-of-high-risk-bladder-cancer/
WASHINGTON — Add-on durvalumab (Imfinzi) reduced the number of early high-risk disease recurrences within the first year in patients with high-risk non-muscle-invasive bladder cancer (NMIBC), according to new analyses from the POTOMAC trial. The phase III study showed that in that first year, 16% of 339 patients who received durvalumab plus bacillus Calmette-Guérin (BCG) induction […]
The post Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-16 20:45:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8